Fasinumab

N/A

Report date: 2022/11/15 10:39:35

Base Information

Drug NameFasinumab
Drug Alias Name法西努单抗fasinumabum法昔人单抗R-475REGN-475 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-Nerve growth factor
TargetsNerve growth factor
Therapy Area/IndicationsLow Back PainBack PainAbdominal Pain +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesSanofiMitsubishi Tanabe Pharma Corp
Active IndicationsOsteoarthritis, KneeOsteoarthritis, Hip
Inactive IndicationsLow Back PainBack PainAbdominal Pain +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG